IO Biotech, Inc , a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform.
infoIO Biotech is a micro cap stock with a total market cap of 133.08M.
infoThey trade on the NASDAQ and had their IPO 1 year and 9 months ago.
infoIO Biotech currently employs 57 people.
infoAs of Wednesday, Aug 23 2023, IO Biotech’s share price is $2.02.
News Relating to IO Biotech
Zacks Investment Research
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
Thursday Jun 15 2023 at 09:32
IO Biotech (IOBT) falls 25% despite achieving the clinical milestone of enrolling 225 patients in the advanced melanoma study evaluating the IO102-IO103/Keytruda combo.
GlobeNewsWire
IO Biotech to Present at the Jefferies Healthcare Conference
Tuesday May 30 2023 at 16:35
NEW YORK, May 30, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on its T-win® technology platform, announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, and Amy Sullivan, the company’s CFO, will be presenting and participating in one-on-one investor meetings at the Jefferies Healthcare Conference to be held June 7-9 in New York City.
GlobeNewsWire
IO Biotech to Participate in March 2023 Investor Conferences
Wednesday Feb 22 2023 at 07:00
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® vaccine platform, today announced participation in two upcoming investor conferences. Mai-Britt Zocca, Ph.D., the company’s President and CEO, will participate in the Novel IO Panel at the Cowen 43rd Annual Health Care Conference, taking place March 6 – 8, 2023 in Boston, MA and will present a corporate overview at the Oppenheimer 33rd Annual Healthcare Conference, taking place virtually March 13 – 15, 2023. Dr. Zocca and Amy Sullivan, the company’s CFO, will be available for one-on-one investor meetings during both conferences.
GlobeNewsWire
IO Biotech to Present at 42nd Annual Cowen Healthcare Conference
Friday Mar 04 2022 at 08:00
NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win® technology platform, announced today it will present at the 42nd Annual Cowen Health Care Conference to be held virtually March 7 – 9, 2022. At the conference, IO Biotech CEO Dr. Mai-Britt Zocca will participate in the Novel IO Panel Discussion.
Pulse2
IO Biotech (IOBT) Stock: $21 Price Target From Morgan Stanley
Friday Dec 03 2021 at 10:55
The shares of IO Biotech Inc (NASDAQ: IOBT) have received a $21 price target from Morgan Stanley. These are the details.
IO Biotech Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
IO Biotech’s Altman Z-score is 2.46 which is in the gray zone. This indicates a level of ambiguity where further analyses are needed to evaluate the company’s financial stability accurately.
Derived from SEC.GOV filing dataopen_in_new
IO Biotech Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has bought $11.10M of common stock in IO Biotech on the stock market with no insider selling.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
IO Biotech’s Income Quality of 0.83 is greater than its Industry Group of 0.69 (20.3% greater)
IO Biotech’s Income Quality of 0.83 is greater than its Major Industry Group of 0.71 (16.9% greater)
IO Biotech’s Income Quality of 0.83 is greater than its Sector of 0.75 (10.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
IO Biotech’s Current Ratio of 10.39 is greater than its Industry Group of 4.76 (118.3% greater)
IO Biotech’s Current Ratio of 10.39 is greater than its Major Industry Group of 4.32 (140.5% greater)
IO Biotech’s Current Ratio of 10.39 is greater than its Sector of 2.6 (299.6% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (-1.8 & -1.27)
Cannot compare a negative PE Ratio (-1.8 & -1.1)
Cannot compare a negative PE Ratio (-1.8 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
IO Biotech’s PB Ratio of 1.27 is in line with its Industry Group of 1.34 (-5.2% lower)
IO Biotech’s PB Ratio of 1.27 is in line with its Major Industry Group of 1.4 (-9.3% lower)
IO Biotech’s PB Ratio of 1.27 is lower than its Sector of 1.62 (-21.6% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
IO Biotech’s ROE of -0.71 is lower than its Industry Group of -0.44 (-61.4% lower)
IO Biotech’s ROE of -0.71 is lower than its Major Industry Group of -0.38 (-86.8% lower)
IO Biotech’s ROE of -0.71 is lower than its Sector of -0.03 (-2266.7% lower)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
IO Biotech’s ROCE of -0.71 is lower than its Industry Group of -0.42 (-69.0% lower)
IO Biotech’s ROCE of -0.71 is lower than its Major Industry Group of -0.37 (-91.9% lower)
IO Biotech’s ROCE of -0.71 is lower than its Sector of -0.04 (-1675.0% lower)
Derived from SEC.GOV filing dataopen_in_new